Enliven Therapeutics, Inc. (NASDAQ:ELVN) Sees Significant Growth in Short Interest

Enliven Therapeutics, Inc. (NASDAQ:ELVN) saw a significant growth in short interest during the month of April. As of April 15th, there was short interest totalling 4,640,000 shares, a growth of 9.7% from the March 31st total of 4,230,000 shares. Based on an average daily volume of 247,800 shares, the short-interest ratio is currently 18.7 days. Approximately 18.3% of the company’s stock are sold short.

Insider Buying and Selling at Enliven Therapeutics

In other Enliven Therapeutics news, COO Anish Patel sold 4,875 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $15.11, for a total value of $73,661.25. Following the transaction, the chief operating officer now directly owns 12,347 shares in the company, valued at $186,563.17. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other news, insider Joseph P. Lyssikatos sold 12,000 shares of the stock in a transaction that occurred on Thursday, February 29th. The stock was sold at an average price of $16.42, for a total value of $197,040.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, COO Anish Patel sold 4,875 shares of the stock in a transaction that occurred on Tuesday, February 6th. The shares were sold at an average price of $15.11, for a total value of $73,661.25. Following the completion of the sale, the chief operating officer now directly owns 12,347 shares of the company’s stock, valued at $186,563.17. The disclosure for this sale can be found here. Insiders have sold 257,516 shares of company stock worth $5,662,173 over the last three months. Insiders own 45.80% of the company’s stock.

Institutional Investors Weigh In On Enliven Therapeutics

Hedge funds have recently modified their holdings of the stock. AJOVista LLC acquired a new stake in shares of Enliven Therapeutics during the fourth quarter worth $28,000. China Universal Asset Management Co. Ltd. purchased a new position in Enliven Therapeutics in the fourth quarter worth $66,000. Exchange Traded Concepts LLC raised its position in Enliven Therapeutics by 34.0% in the fourth quarter. Exchange Traded Concepts LLC now owns 8,708 shares of the company’s stock worth $121,000 after acquiring an additional 2,208 shares in the last quarter. SG Americas Securities LLC purchased a new position in Enliven Therapeutics in the third quarter worth $157,000. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in Enliven Therapeutics by 9.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,305 shares of the company’s stock worth $170,000 after acquiring an additional 1,029 shares in the last quarter. 95.08% of the stock is owned by institutional investors and hedge funds.

Enliven Therapeutics Price Performance

Shares of NASDAQ ELVN opened at $18.10 on Thursday. The stock has a fifty day moving average price of $17.20 and a 200 day moving average price of $14.59. Enliven Therapeutics has a 1-year low of $9.80 and a 1-year high of $26.00. The company has a market cap of $850.88 million, a PE ratio of -8.26 and a beta of 1.06.

Enliven Therapeutics (NASDAQ:ELVN) last issued its quarterly earnings results on Thursday, March 14th. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.56) by $0.09. Analysts anticipate that Enliven Therapeutics will post -2.16 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Mizuho began coverage on Enliven Therapeutics in a report on Tuesday, April 9th. They issued a “buy” rating and a $34.00 price objective for the company.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.